Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Phase II results presented for ZYN-002 in children and adolescents with DEE

June 18, 2021

Biogen discontinues gosuranemab based on phase II data in Alzheimer's disease

June 17, 2021

Therapeutic Solutions reports preclinical data on low-dose naltrexone for schizophrenia

June 17, 2021

Japansese researchers describe new delta-opioid receptor agonists

June 17, 2021

Servier and Oncodesign's collaboration in Parkinson's selects preclinical candidate

June 16, 2021

FDA approves IND for phase IIb PORTICO study of vafidemstat in borderline personality disorder

June 16, 2021

Chinese researchers patent NMDA receptor antagonists

June 16, 2021

Avidea advances lead SNAPvax TV candidate for MS toward clinic

June 16, 2021

FDA clears IND application for phase II study of LPCN-1154 in postpartum depression

June 16, 2021

XWPharma reports phase I data on XW-10172 for sleep disorders

June 15, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 19, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 19, 2026
Authorities work to quickly sequence Ebola species in latest outbreak
BioWorld
If the recent hantavirus outbreak wasn’t enough to keep public health officials busy, a new Ebola virus disease outbreak has been confirmed by authorities in the...
WHO declares Ebola outbreak a public health emergency of international concern
BioWorld
The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
Nxera Pharma prepares and tests new GPR17 antagonists
BioWorld Science
Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...